# Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

> **NCT01430169** · PHASE2 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Peyronie's Disease

## Interventions

- **BIOLOGICAL:** AA4500

## Key facts

- **NCT ID:** NCT01430169
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430169, "Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01430169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*